Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review
Oncology Research and Treatment · 2024
DOI: 10.1159/000540662 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Yang-Kai Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College of Fujian Medical University, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Phenylurea Compounds. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
Patients with hepatocellular carcinoma (HCC) and inferior vena cava tumor thrombus (IVCTT) have poor prognosis. Combination therapy involving the blockade of programmed cell death protein 1 (PD-1) and tyrosine kinase inhibitors is an efficient treatment strategy for advanced HCC. However, surgical treatment after a combination of systemic therapy and transarterial chemoembolization (TACE) for HCC with IVCTT has not been widely reported, and the efficacy and safety of this treatment have not been studied.
Methods
In the 21 cases reported herein, the patients were treated with TACE, lenvatinib, and PD-1 blockade. The treatment responses, progression-free survival (PFS), overall survival (OS), disease control rate, and toxicities were evaluated, and the related literature was reviewed.
Results
The overall response and disease control rates were 66.7% and 85.7%, respectively. The median PFS time was 16.0 months, with a 1-year PFS rate of 55.60%. The median OS was not reached, with a 1-year OS rate of 66.70%. Four patients underwent hepatectomy without serious complications and survived for 29.1, 24.7, 14.2, and 13.8 months. Three patients survived tumor-free, and 1 patient experienced intrahepatic recurrence. Pathological complete response and major pathological responses were observed in 1 and 3 patients, respectively. Treatment-related adverse events of any grade occurred in 8/9 patients (88.9%), and grade 3 treatment-related adverse events occurred in 1 patient.
Conclusion
The combination of TACE, lenvatinib, and PD-1 is effective for HCC with IVCTT and has acceptable adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shengli Clinical Medical College of Fujian Medical University, Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
- Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
Zitieren
APA
Fu, Y. K., Li, Y. N., Liu, D. Y., Zeng, Z. X., Wu, J. Y., Wu, J. Y., Wang, J. X., Li, H., Ou, X. Y., & Yan, M. L. (2024). Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review. Oncology Research and Treatment. https://doi.org/10.1159/000540662
Vancouver
Fu YK, Li YN, Liu DY, Zeng ZX, Wu JY, Wu JY, et al. Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review. Oncology Research and Treatment. 2024. doi:10.1159/000540662
BibTeX
@article{Fu2024,
author = {Fu, Yang-Kai and Li, Yi-Nan and Liu, De-Yi and Zeng, Zhen-Xin and Wu, Jia-Yi and Wu, Jun-Yi and Wang, Jin-Xiu and Li, Han and Ou, Xiang-Ye and Yan, Mao-Lin},
title = {Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review},
journal = {Oncology Research and Treatment},
year = {2024},
doi = {10.1159/000540662}
}
EUVIMED